Compare Everest Medicines Ltd. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 13.72% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -217.30
2
Risky -
3
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-46.23%
0%
-46.23%
6 Months
-37.2%
0%
-37.2%
1 Year
38.99%
0%
38.99%
2 Years
168.83%
0%
168.83%
3 Years
32.03%
0%
32.03%
4 Years
-61.05%
0%
-61.05%
5 Years
0%
0%
0.0%
Everest Medicines Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
556.73%
EBIT Growth (5y)
13.72%
EBIT to Interest (avg)
-42.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.10
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
328
Industry P/E
Price to Book Value
1.47
EV to EBIT
-15.88
EV to EBITDA
-26.81
EV to Capital Employed
1.72
EV to Sales
3.56
PEG Ratio
3.18
Dividend Yield
NA
ROCE (Latest)
-10.81%
ROE (Latest)
0.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,850.90
766.20
141.57%
Operating Profit (PBDIT) excl Other Income
-249.20
-680.80
63.40%
Interest
25.20
24.10
4.56%
Exceptional Items
-343.90
-383.50
10.33%
Consolidate Net Profit
-322.90
-1,129.10
71.40%
Operating Profit Margin (Excl OI)
-226.40%
-1,077.60%
85.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 141.57% vs 450.43% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 71.40% vs -21.01% in Dec 2024
About Everest Medicines Ltd. 
Everest Medicines Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






